NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
Clinical Trials
23 trialsNCT07465289 2026-03-11
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Pharma
Phase 3 Not yet recruiting
NCT07304154 2026-03-10
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Not yet recruiting
NCT07298928 2026-03-06
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
The Children's Hospital of Zhejiang University School of Medicine
Phase NA Not yet recruiting
NCT07221838 2026-03-03
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Not yet recruiting
NCT07392528 2026-02-11
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07033559 2026-01-28
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
Thymia Limited
Not yet recruiting
NCT07333196 2026-01-21
Tongji NADs Cohort
Tongji Hospital
Not yet recruiting
NCT07337395 2026-01-13
PROMPT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Not yet recruiting
NCT07323316 2026-01-07
HARMONY 360
Ad scientiam
Phase NA Not yet recruiting
NCT06866652 2025-11-24
MyaRESP
Institut de Myologie, France
Not yet recruiting
NCT07243366 2025-11-21
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
Guangdong ProCapZoom Biosciences Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07226830 2025-11-12
BioDigit MG-03
BioSensics
Not yet recruiting
NCT07224386 2025-11-04
BioDigit MG-02
BioSensics
Not yet recruiting
NCT07125105 2025-08-15
APART-MG
Universite du Littoral Cote d'Opale
Phase NA Not yet recruiting
NCT07079020 2025-07-22
Efgartigimod for Consolidation Therapy in gMG
Da, Yuwei, M.D.
Not yet recruiting
NCT06958939 2025-05-06
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Not yet recruiting
NCT06933563 2025-04-18
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT06836973 2025-03-25
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Da, Yuwei, M.D.
Phase 2/3 Not yet recruiting
NCT06827587 2025-02-14
Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis
First Affiliated Hospital of Wenzhou Medical University
Phase NA Not yet recruiting
NCT06759948 2025-01-06
KY2024-853
Huashan Hospital
Phase 1 Not yet recruiting
NCT06485232 2025-01-01
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1 Not yet recruiting
NCT06723548 2024-12-09
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
First Affiliated Hospital of Wenzhou Medical University
Phase 4 Not yet recruiting